Heat Biologics (HTBX) Plans Presentation ofTopline HS-110 + Opdivo Phase 1b Study in NSCLC at Upcoming Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Heat Biologics to Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results at the International Society for the Study of Lung Cancer Annual Meeting
November 17, 2016 7:00 AM ESTDURHAM, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a leader in the development of gp96-based immunotherapies that are designed to activate a patients immune system to fight cancer, announced that it will be reporting topline results from the Phase Ib study evaluating HS-110, in combination with Bristol-Myers Squibbs anti-PD-1 checkpoint inhibitor, nivolumab... More
